Reported about 1 year ago
Taigen Biopharma's first biosimilar drug, TX01, received FDA approval for Biologics License Application (BLA) on June 29 in Taiwanese time, allowing the company to enter the world's largest biosimilar drug market in the US. This marks Taigen's first FDA approval and Taiwan's first FDA-approved biosimilar drug, as well as Asia's first FDA-approved filgrastim biosimilar drug. The drug, Nypozi, is used for treating chemotherapy-induced neutropenia and is the fourth filgrastim biosimilar to be approved by the FDA. With this milestone achievement, Taigen plans to expand its biopharmaceutical business in the US market and offer Contract Development and Manufacturing Organization (CDMO) services for biopharmaceuticals.
Source: YAHOO